引用本文:王谷云,林丽娥.不同年龄段重型β-地中海贫血患儿接受异基因造血干细胞移植后的疗效比较[J].中国临床新医学,2023,16(11):1125-1129.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 307次   下载 545 本文二维码信息
码上扫一扫!
分享到: 微信 更多
不同年龄段重型β-地中海贫血患儿接受异基因造血干细胞移植后的疗效比较
王谷云,林丽娥
570311 海口,海南省人民医院血液内科
摘要:
[摘要] 目的 比较不同年龄段重型β-地中海贫血患儿接受异基因造血干细胞移植后的疗效。方法 回顾性分析2017年3月1日至2023年2月28日于海南省人民医院血液内科行异基因造血干细胞移植的41例不同年龄段重型β-地中海贫血患儿的临床资料,以5岁为界线,分为2~5岁组20例,6~15岁组21例,比较两组患儿移植后植入成功率、无地贫生存率、移植物抗宿主病(GVHD)发生率以及感染等移植相关并发症发生率等。结果 2~5岁组患儿移植后呼吸道感染发生率低于6~15岁组,差异有统计学意义(P<0.05)。两组植入成功率、GVHD发生率、无地贫生存率和肝静脉闭塞病(VOD)发生率比较差异无统计学意义(P>0.05)。结论 2~5岁组患儿移植后的并发症少,生存质量高,可为临床治疗提供优选的指导意义。
关键词:  地中海贫血  异基因造血干细胞移植  疗效  年龄  并发症
DOI:10.3969/j.issn.1674-3806.2023.11.05
分类号:R 556.6+1
基金项目:
Comparison of therapeutic effects of allogeneic hematopoietic stem cell transplantation in beta-thalassemia major children of different ages
WANG Gu-yun, LIN Li-e
Department of Hematology, Hainan General Hospital, Haikou 570311, China
Abstract:
[Abstract] Objective To compare the therapeutic effects of allogeneic hematopoietic stem cell transplantation in beta-thalassemia major children of different ages. Methods The clinical data of 41 beta-thalassemia major children of different ages who received treatment at the Department of Hematology of Hainan General Hospital from March 1, 2017 to February 28, 2023 were retrospectively analyzed. The patients were divided into 2-5 years old group(20 cases) and 6-15 years old group(21 cases) at the age of five years. The success rate of implantation after transplantation, thalassemia-free survival rate, incidence of graft-versus-host disease(GVHD), and the rate of infection and other transplant-related complications were compared between the patients in the two groups. Results The incidence of respiratory tract infection in the 2-5 years old group after transplantation was significantly lower than that in the 6-15 years old group, and the difference was statistically significant(P<0.05). There were no significant differences in the success rate of implantation, the incidence of GVHD, the thalassemia-free survival rate and the incidence of hepatic veno-occlusive disease(VOD) between the two groups(P>0.05). Conclusion The pediatric patients in the 2-5 years old group has fewer complications and high quality of life after transplantation, which provides optimal guiding significance for clinical treatment.
Key words:  Thalassemia  Allogeneic hematopoietic stem cell transplantation  Therapeutic effect  Age  Complication